[go: up one dir, main page]

MX7262E - Procedimiento para preparar composiciones de materia farmacologicamente activas a base de venenos o fracciones de venenos de serpientes - Google Patents

Procedimiento para preparar composiciones de materia farmacologicamente activas a base de venenos o fracciones de venenos de serpientes

Info

Publication number
MX7262E
MX7262E MX8210020U MX1002082U MX7262E MX 7262 E MX7262 E MX 7262E MX 8210020 U MX8210020 U MX 8210020U MX 1002082 U MX1002082 U MX 1002082U MX 7262 E MX7262 E MX 7262E
Authority
MX
Mexico
Prior art keywords
poisons
fractions
procedure
active material
pharmacologically active
Prior art date
Application number
MX8210020U
Other languages
English (en)
Inventor
William E Haast
Original Assignee
William E Haast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William E Haast filed Critical William E Haast
Publication of MX7262E publication Critical patent/MX7262E/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX8210020U 1981-04-07 1982-04-07 Procedimiento para preparar composiciones de materia farmacologicamente activas a base de venenos o fracciones de venenos de serpientes MX7262E (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/251,745 US4341762A (en) 1981-04-07 1981-04-07 Use of snake venoms for treatment of neurological and related disorders

Publications (1)

Publication Number Publication Date
MX7262E true MX7262E (es) 1988-03-03

Family

ID=22953228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX8210020U MX7262E (es) 1981-04-07 1982-04-07 Procedimiento para preparar composiciones de materia farmacologicamente activas a base de venenos o fracciones de venenos de serpientes

Country Status (6)

Country Link
US (1) US4341762A (es)
EP (1) EP0063091B1 (es)
JP (1) JPS57179120A (es)
DE (1) DE3273730D1 (es)
IL (1) IL65405A (es)
MX (1) MX7262E (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US4657761A (en) * 1985-06-05 1987-04-14 Pinto Cesar M Polyvalent non-specific immuno-stimulating vaccine and method
EP0246861B1 (en) * 1986-05-19 1993-03-17 Ventech Research, Inc. Use of compositions based on crotoxine, for the manufacture of a medicament for the treatment of carcinomas
US4741902A (en) * 1986-07-14 1988-05-03 Haast William E Compositions for treatment of neurological and related disorders
US4806346A (en) * 1986-12-16 1989-02-21 American Home Products Corporation Method for isolation of antigen specific immunoglobulin
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5232695A (en) * 1987-12-23 1993-08-03 G. D. Searle & Co. Method of ameliorating herpes simplex virus infections using purified nerve growth factor
US4877741A (en) * 1988-10-24 1989-10-31 The United States Of America As Represented By The Secretary Of The Air Force Treatment of human plasma with brown recluse spider toxin to emulate a lupus anticoagulant
US5196403A (en) * 1989-01-27 1993-03-23 Biogen, Inc. Method of inhibiting platelet activation
US5182260A (en) * 1989-01-27 1993-01-26 Biogen, Inc. Dna sequences encoding snake venom inhibitors of platelet activation processes for producing those inhibitors and compositions using them
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5856363A (en) * 1992-06-30 1999-01-05 John B. Davidson Methods of using ajoene
US5863954A (en) * 1992-06-30 1999-01-26 John B. Davidson Contraceptive method using ajoene
US5948821A (en) * 1992-06-30 1999-09-07 John B. Davidson Methods of using ajoene
US5981602A (en) * 1992-06-30 1999-11-09 John B. Davidson Methods of using Ajoene for inhibiting integrin-mediated cell-cell fusion
US6177475B1 (en) 1992-06-30 2001-01-23 Billings Pharmaceuticals, Inc. Methods of using integrin modulators for treatment of inflammation
US5863955A (en) * 1992-06-30 1999-01-26 John B. Davidson Methods of using ajoene to inhibit an immune response
CA2076944A1 (en) * 1992-06-30 1993-12-31 Alexander V. Tatarintsev Ajoene as an agent for inhibiting symptoms and growth of aids virus and changes at the cellular level
US5676974A (en) * 1992-10-23 1997-10-14 Santiago H. Valdes Pharmaceutical compositions containing giroxina and phospholipase A2 and methods of increasing a patient's CD4 count using the pharmaceutical compositions
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
DE69534371T2 (de) * 1994-03-31 2006-05-24 Biomed Comm Inc., Seattle Wachstumsfaktoren enthaldende therapeutische homöopathische verdünnungen und verwendung
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US6316602B1 (en) * 1994-05-03 2001-11-13 Binie V. Lipps Beta taipoxin as a cell growth factor and method
FR2769226B1 (fr) * 1997-10-06 2000-06-02 Centre Nat Rech Scient Utilisation des bloqueurs des canaux potassium dans le traitement des maladies neurologiques
SE0003619L (sv) * 1999-12-28 2001-08-23 Bjoern Oertenheim Farmaceutisk komposition och metod för dess framställning
US7045663B2 (en) * 2001-07-10 2006-05-16 Billings Pharmaceuticals, Inc. Chiral integrin modulators and methods of use thereof
RU2261719C2 (ru) * 2000-10-27 2005-10-10 Писарев Александр Геннадьевич Водно-спиртовая настойка
EP1391207A1 (en) * 2001-04-24 2004-02-25 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
WO2003072543A2 (en) * 2002-02-21 2003-09-04 Quark Biotech, Inc. Methods of preventing or treating brain ischemia or brain injury
BG65618B1 (bg) * 2003-01-22 2009-03-31 Борис Алексиев Използване на противозмийски серум за лечение на мозъчен инсулт
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US20050255097A1 (en) * 2004-01-26 2005-11-17 Paul Reid Modified venom and venom components as anti-retroviral agents
US20080234388A1 (en) * 2004-03-10 2008-09-25 Davidson John B Integrin Modulators and Methods for their Use
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
DE602005027582D1 (de) * 2004-08-16 2011-06-01 Medical Res Fund Of Tel Aviv Sourasky Medical Ct Verfahren und zusammensetzung zur modulation des systemischen entzündlichen reaktionssyndroms (sirs)
US20060045875A1 (en) * 2004-09-02 2006-03-02 Reid Paul F Method of use of crotoxin as an anti-retroviral agent
US8034777B2 (en) * 2004-09-23 2011-10-11 Receptopharm, Inc. Modified anticholinergic neurotoxins as modulators of the autoimmune reaction
US20060088858A1 (en) * 2004-10-25 2006-04-27 Reid Paul F Modified venom and venom components as anti-retroviral agents
US20060088843A1 (en) * 2004-10-25 2006-04-27 Reid Paul F Modified venom and venom components as anti-retroviral agents
DE102004055891B4 (de) * 2004-11-19 2007-08-30 Wiesner, Henning, Prof., Dr. Gemische von Schlangengiften zur Krankheitsbekämpfung
GB0516586D0 (en) * 2005-08-12 2005-09-21 Smith & Nephew Ultrasound therapy for diabetic peripheral neuropathy
US7902152B2 (en) * 2005-12-20 2011-03-08 Receptopharm, Inc. Use of cobratoxin as an analgesic
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
US7758894B2 (en) * 2006-11-06 2010-07-20 Receptopharm, Inc. Modified elapid venoms as stimulators of the immune reaction
US20090209468A1 (en) * 2006-12-19 2009-08-20 Reid Paul F Alpha-neurotoxin proteins with anti-inflammatory properties and uses thereof
US7259237B1 (en) * 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
TR200708925A1 (tr) * 2007-12-26 2009-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan flurbiprofen ve kas gevşetici kombinasyonları
WO2009131435A1 (en) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
US9220743B2 (en) 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
IT1402503B1 (it) * 2010-07-22 2013-09-13 Satanassi Antidoto per morso di serpenti velenosi
KR101802515B1 (ko) 2016-12-09 2017-11-29 아주대학교산학협력단 Ａｐ를 포함하는 염증성 질환의 예방 또는 치료용 조성물
WO2018106062A1 (ko) * 2016-12-09 2018-06-14 아주대학교산학협력단 Ap 또는 ｎｍ를 포함하는 염증성 질환의 예방 또는 치료용 조성물
KR102340531B1 (ko) * 2019-07-02 2021-12-21 독립바이오제약(주) Agkistrodon piscivorous piscivorous로부터 유래된 뱀독을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물
WO2021002642A1 (ko) * 2019-07-02 2021-01-07 독립바이오제약(주) 뱀독을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012502A (en) * 1973-09-21 1977-03-15 Buren Philpot V Jun Snake venom inhibitor material and method of purification
US4126676A (en) * 1977-07-22 1978-11-21 Sanders Murray J Modified neurotoxin derived from naja genus snake venom
US4292308A (en) * 1979-08-21 1981-09-29 Biotherapeutics, Inc. Treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents

Also Published As

Publication number Publication date
IL65405A0 (en) 1982-07-30
EP0063091A2 (en) 1982-10-20
JPS57179120A (en) 1982-11-04
DE3273730D1 (en) 1986-11-20
EP0063091A3 (en) 1983-06-22
IL65405A (en) 1985-06-30
US4341762A (en) 1982-07-27
EP0063091B1 (en) 1986-10-15

Similar Documents

Publication Publication Date Title
MX7262E (es) Procedimiento para preparar composiciones de materia farmacologicamente activas a base de venenos o fracciones de venenos de serpientes
ES548071A0 (es) Procedimiento de obtencion de un material para cojinetes
DE58903297D1 (de) Materialpruefanlage.
NO900631L (no) Fremgangsmaate for fremstilling av bleket lignocellulosemateriale.
BR8503565A (pt) Embalagem para a distribuicao de substancias volateis
DK163009C (da) Erstatningsmateriale for jordoverflade
BR8804281A (pt) Composicao de materia
JPS5515859A (en) Base material for asphalt waterrproof
NO901486D0 (no) Fotopolymeriserbart belegningsmateriale.
FI905140A7 (fi) Materiaali
DK244185D0 (da) Fremgangsmaade til indkapsling af organisk materiale
AT381903B (de) Matrizenform
AR222500A1 (es) N-benzoil-n'-ter-alcoxicarbonilfenil-ureas y-tioureas sustituidas,procedimiento para su obtencion y composiciones insecticidas a base de dichos compuestos
ES522732A0 (es) "procedimiento para la preparacion de composiciones a base de fluoroclorohidrocarburos"
BR9003711A (pt) Receptaculo para material solido elastico
DE69029346D1 (de) Entwicklungsgerät für lichtempfindliches Material
PT77799A (fr) Procede de preparations de compositions fongicides a base de phosethyl al et cynoxanil
TR25267A (tr) Ince taneli toz halindeki yakitlarin gazlastiril- masina mahsus tertibat
BR8207657A (pt) Germinador e uso de material textil para a producao de um germinador
BR7805467A (pt) Instalacoes para a fundicao de material ceramico
DE59005884D1 (de) Photopolymerisierbares Gemisch und daraus hergestelltes Aufzeichnungsmaterial.
DK18985D0 (da) Fremgangsmaade til fremstilling af et farmakologisk virksomt sulfonylurinstofderivat
KR840002534U (ko) 계산지 받침판용 클맆
RO78748A2 (ro) Ansamblu pasitor de sustinere in subteran
ATA12389A (de) Tisch